Last reviewed · How we verify
NCT05724472
Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
Phase 1 trial testing rVSV∆G-SEBOV-GP Vaccine or Placebo in Ebola Sudan Virus Disease in 36 participants. Completed in 9 January 2024.
9 January 2024
Quick facts
| Lead sponsor | International AIDS Vaccine Initiative |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 36 |
| Start date | 19 June 2023 |
| Primary completion | 9 January 2024 |
| Estimated completion | 9 January 2024 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- rVSV∆G-SEBOV-GP Vaccine or Placebo — full drug profile →
Conditions studied
- Ebola Sudan Virus Disease — all drugs for Ebola Sudan Virus Disease →
Sponsor
International AIDS Vaccine Initiative — full company profile →
Who can join
Adults 18 to 50, any sex, with Ebola Sudan Virus Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
An update on nonhuman primate usage for drug and vaccine evaluation against filoviruses.
de La Vega MA, Xiii A, Massey S, Spengler JR, et al · · 2024 · cited 4× · PMID 39090822 · DOI 10.1080/17460441.2024.2386100 -
Dual role of rVSV vectors in prophylactic and therapeutic innovation: a comprehensive bibliometric and clinical trial perspective.
Chen Y, Zhang Y, Zhang Y, Bie C, et al · · 2026 · PMID 41777881 · DOI 10.3389/fimmu.2026.1711059
Verify or expand the search:
- PubMed search for NCT05724472
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other International AIDS Vaccine Initiative trials
Trials by the same sponsor.
- NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
- NCT06617091 — A Trial of a Gorilla Adenovirus Vectored Networked Epitopes Vaccine, Administered to Healthy Adults Living Without and W · Phase 1 · recruiting
- NCT06272812 — A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic R · Phase 2 · recruiting
- NCT06449196 — Mosaic HIV-1 Envelope Trimer Immunogens Administered to People Living with HIV (PLWH) in Africa · EARLY_PHASE1 · withdrawn
- NCT05414786 — A Study to Evaluate the Safety and Immunogenicity of eOD-GT8 60mer mRNA Vaccine (mRNA-1644) · Phase 1 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05724472 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by International AIDS Vaccine Initiative
- Last refreshed: 6 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05724472.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing